The USFDA has approved an injection named Tirzepatide for the treatment of adults with type 2 diabetes, supplementing diet and exercise. The drug activates the receptors of both the hormones, namely, glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP) which are responsible for controlling blood sugar. The evidence The approval was based on a study involving the evaluation of three different doses (5 mg, 10 mg, and 15 mg) of the drug in five clinical trials as either a monotherapy or in combination with other diabetes medicines.
The efficacy of the drug was compared to a placebo, a GLP-1 receptor agonist (semaglutide), and two long-acting insulin analogs. The drug was administered by subcutaneous injection once a week, with the dose adjusted as tolerated to meet blood sugar goals. Obesity was common among the study participants with an average body mass…
